Corpus Intelligence IC Memo — NEBRASKA ORTHOPAEDIC HOSPITAL LLC 2026-04-26 03:50 UTC
IC Memo — NEBRASKA ORTHOPAEDIC HOSPITAL LLC
Investment Committee Memorandum | NE | 24 beds | Grade C | EBITDA uplift $8.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NEBRASKA ORTHOPAEDIC HOSPITAL LLC

CCN 280129 | DOUGLAS, NE | 24 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

NEBRASKA ORTHOPAEDIC HOSPITAL LLC is a 24-bed suburban community hospital in DOUGLAS, NE with $112.1M in net patient revenue and a 22.5% operating margin. The hospital serves a payer mix of 43.9% Medicare, 3.8% Medicaid, and 52.3% commercial.

Thesis: Turnaround. Our ML models identify $8.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 22.5% to 29.8% (+736bps).

Net Revenue HCRIS$112.1M
Current EBITDA COMPUTED$25.2M
Operating Margin COMPUTED22.5%
Occupancy HCRIS6.0%
Revenue / Bed COMPUTED$4.7M
Net-to-Gross HCRIS41.5%
Distress Probability ML54.9%

2. Market Context & Competitive Position

98
NE Hospitals
-6.3%
State Median Margin
65
Comparable Hospitals

NE has 98 Medicare-certified hospitals with a median operating margin of -6.3%. The target's margin of 22.5% places it above the state median. Among 65 size-comparable peers (12-48 beds), the median margin is -5.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-48), prioritizing same-state peers. 65 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NEBRASKA ORTHOPAEDIC HOSPITAL (Target)NE24$112.1M22.5%
BEATRICE COMMUNITY HOSPITALNE25$84.6M-1.2%
LINCOLN SURGICAL HOSPITALNE20$80.9M18.8%
MIDWEST SURGICAL HOSPITALNE19$70.1M36.2%
PHELPS MEMORIAL HEALTH CENTERNE25$69.0M8.2%
SIDNEY REGIONAL MEDICAL CENTERNE19$68.0M0.8%
COMMUNITY HOSPITAL ASSOCOCIATINE25$56.0M-7.4%
NEBRASKA SPINE HOSPITALNE34$55.9M49.5%
YORK GENERAL HOSPITAL INCNE25$52.3M-1.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $8.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.4M+210bp18mo
Cost to Collect4.5%2.5%$2.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.4M+122bp9mo
Clean Claim Rate88.0%96.0%$72K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.4M
Cost to Collect
$2.2M
Denial Rate Reduction
$2.2M
A/R Days Reduction
$1.4M
Clean Claim Rate
$72K
Total EBITDA Uplift$8.3M
Current EBITDA$25.2M
+ RCM Uplift+$8.3M
Pro Forma EBITDA$33.4M
Current Margin22.5%
Pro Forma Margin29.8%
WC Released (1x)$4.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$38.8M$248.7M6.42x45.0%
Base (11x exit)10.0x11.0x$38.8M$286.2M7.38x49.2%
Bull Case9.0x11.0x$34.9M$326.0M9.34x56.4%
Bull (12x exit)9.0x12.0x$34.9M$365.9M10.49x60.0%
Bear Case11.0x10.0x$42.6M$194.9M4.57x35.5%
Bear (11x exit)11.0x11.0x$42.6M$228.2M5.35x39.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 6.0%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 54.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 65 hospitals with 12-48 beds
  • Same-state prioritization (n=66)
  • Comp margins: P25=-13.0% / P50=-5.2% / P75=0.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.